Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19709498 | 0.81 | MEN1 (0.33) | MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL691871 | 0.73 | MAPT (0.49) | MEN1KMT2AMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL12233968 | 0.73 | LIPG (0.54) | NPSR1HPGDHDAC8 | |
| SCHEMBL18285869 | 0.70 | DYRK1A (0.42) | MEN1KMT2AMAPTNPSR1POLB | |
| SCHEMBL16125870 | 0.70 | HSD17B10 (0.39) | HRH3MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL4619770 | 0.69 | SMN1; SMN2 (0.44) | HRH3KMT2AMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL2315498 | 0.69 | HRH3 (0.43) | HRH3KMT2AMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL2318862 | 0.69 | NSD1 (0.47) | HRH3KMT2AMAPTSMN1; SMN2DYRK1A | |
| SCHEMBL7961498 | 0.69 | HRH3 (0.43) | HRH3KMT2AMAPTNPSR1SMN1; SMN2 | |
| SCHEMBL31296525 | 0.69 | HRH3 (0.43) | HRH3KMT2AMAPTNPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597370-B2 | 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190144403-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-16 | — | — | US | disclosed |
| WO-2017214005-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144403-A1 | 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, LPL, CEL | HRH3 2683/4885MEN1 4792/4885KMT2A 1810/4885 |
| US-10597370-B2 | 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors | LIPG, LPL, CEL | HRH3 2683/4885MEN1 4792/4885KMT2A 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.